OPEN-LABEL RANDOMIZED CONTROLLED TRIAL OF VONOPRAZAN AND ESOMEPRAZOLE IN FIRST-LINE TRIPLE THERAPY AGAINST HELICOBACTER PYLORI INFECTION

被引：2
|
作者：
Tamaki, Hiroyuki
Morita, Masahiro
Noda, Teruyo
Izuta, Masako
Kubo, Atsushi
Ogawa, Chikara
Matsunaka, Toshihiro
Shibatoge, Mitsushige
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)31120-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1190
引用
收藏
页码：S248 / S248
页数：1
相关论文
共 50 条
  • [21] Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial
    Tian, Xue-li
    Suo, Bao-jun
    Zhang, Hua
    Lu, Hao-ping
    Li, Cai-ling
    Zhang, Yu-xin
    Ren, Xin-lu
    Yao, Xing-yu
    Zhou, Li-ya
    Song, Zhi-qiang
    [J]. HELICOBACTER, 2023, 28 (01)
  • [22] Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial
    Suo, Baojun
    Tian, Xueli
    Zhang, Hua
    Lu, Haoping
    Li, Cailing
    Zhang, Yuxin
    Ren, Xinlu
    Yao, Xingyu
    Zhou, Liya
    Song, Zhiqiang
    [J]. CHINESE MEDICAL JOURNAL, 2023, 136 (08) : 933 - 940
  • [23] Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial
    Suo Baojun
    Tian Xueli
    Zhang Hua
    Lu Haoping
    Li Cailing
    Zhang Yuxin
    Ren Xinlu
    Yao Xingyu
    Zhou Liya
    Song Zhiqiang
    [J]. 中华医学杂志(英文版), 2023, 136 (08)
  • [24] Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial (vol 381, pg 205, 2013)
    Liou, J. M.
    Chen, C. C.
    Chen, M. J.
    [J]. LANCET, 2013, 381 (9874): : 1276 - 1276
  • [25] A Randomized Controlled Trial Comparing the First-Line Eradication Rate Using Vonoprazan or PPI for Helicobacter pylori Infectious Gastritis
    Maruyama, Masafumi
    Kubota, Daisuke
    Miyajima, Masayuki
    Kimura, Takefumi
    Tokutake, Koujiro
    Imai, Ryujiro
    Fujisawa, Toru
    Mori, Hiromitsu
    Matsuda, Yoshiaki
    Wada, Shuichi
    Kiyosawa, Kendo
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S1269 - S1269
  • [26] Prospective Randomized Controlled Trial to Compare Triple Therapy (TT), Sequential Therapy (ST), and Concomitant Therapy (CT) as First-Line Treatments for Helicobacter pylori Infection
    Hussain, Ikram
    Leong, Ang Tiing
    [J]. DIGESTION, 2014, 89 (01) : 75 - 75
  • [27] Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial
    Georgopoulos, Sotirios D.
    Papastergiou, Vasilios
    Martinez-Gonzalez, Beatriz
    Xirouchakis, Elias
    Familias, Ioannis
    Sgouras, Dionysis
    Mentis, Andreas
    Karatapanis, Stylianos
    [J]. ANNALS OF GASTROENTEROLOGY, 2018, 31 (02): : 205 - 210
  • [28] Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial
    Chen, Chen
    Zhang, Daya
    Huang, Shimei
    Zeng, Fan
    Li, Da
    Zhang, Xiaodong
    Chen, Runxiang
    Chen, Shiju
    Wang, Jun
    Bai, Feihu
    [J]. BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [29] Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection
    Fu, Wei
    Song, Zhiqiang
    Zhou, Liya
    Xue, Yan
    Ding, Yu
    Suo, Baojun
    Tian, Xueli
    Wang, Li
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (06) : 1580 - 1589
  • [30] Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection
    Wei Fu
    Zhiqiang Song
    Liya Zhou
    Yan Xue
    Yu Ding
    Baojun Suo
    Xueli Tian
    Li Wang
    [J]. Digestive Diseases and Sciences, 2017, 62 : 1580 - 1589
12345